Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhenfang Liu

Showing results (91-100 of 92) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 92 results.
Clinical Lymphoma, Myeloma & Leukemia|March 9, 2024
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective StudyXiaoshuai Zhang, Na Xu, Yunfan Yang, et al.
Blood|July 24, 2024
A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapyXiaoshuai Zhang, Bingcheng Liu, Jian Huang, et al.
Pageof 10

Showing results (91-100 of 92) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 92 results.
Clinical Lymphoma, Myeloma & Leukemia|March 9, 2024
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective StudyXiaoshuai Zhang, Na Xu, Yunfan Yang, et al.
Blood|July 24, 2024
A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapyXiaoshuai Zhang, Bingcheng Liu, Jian Huang, et al.
Pageof 10